Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO), Resmed (RMD) and Envista Holdings (NVST)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bausch + Lomb Corporation (BLCO)
J.P. Morgan analyst Robbie Marcus maintained a Hold rating on Bausch + Lomb Corporation on July 30 and set a price target of $13.00. The company's shares closed last Friday at $13.50, close to its 52-week low of $13.16.
According to TipRanks.com, Marcus is a 4-star analyst with an average return of 8.8% and a 52.8% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Merit Medical Systems.
Bausch + Lomb Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $14.69, implying an 8.2% upside from current levels. In a report issued on July 30, Needham also maintained a Hold rating on the stock.
Resmed (RMD)
J.P. Morgan analyst David Low maintained a Buy rating on Resmed yesterday and set a price target of $310.00. The company's shares closed last Friday at $279.20.
According to TipRanks.com, Low is a 4-star analyst with an average return of 7.6% and a 57.0% success rate. Low covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Cochlear, and CSL.
Resmed has an analyst consensus of Strong Buy, with a price target consensus of $295.40, implying a 4.8% upside from current levels. In a report released yesterday, KeyBanc also maintained a Buy rating on the stock with a $298.00 price target.
Envista Holdings (NVST)
J.P. Morgan analyst Rachel Vatnsdal maintained a Hold rating on Envista Holdings yesterday and set a price target of $20.00. The company's shares closed last Friday at $20.83.
According to TipRanks.com, Vatnsdal is a 1-star analyst with an average return of -1.2% and a 39.3% success rate. Vatnsdal covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Twist Bioscience, and Myriad Genetics.
Envista Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $22.17, which is a 9.6% upside from current levels. In a report issued on July 29, UBS also maintained a Hold rating on the stock with a $22.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from J.P. Morgan
J.P. Morgan analyst David Low maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per yesterday and set a price target of A$48.00. The company's shares closed yesterday at A$42.88. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Low is a 4-star analyst with an average return of 7.6% and a 57.02% success rate. Low covers the Healthcare sector, focusing on stocks such as Resmed, Cochlear , and CSL. Currently, the analyst consensus on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per is a Strong Buy with an average price target of A$45.42, a 5.92% upside from current levels. In a report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a A$48.00 price target. The company has a one-year high of A$44.12 and a one-year low of A$32.04. Currently, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per has an average volume of 835K.
Business Insider
a day ago
- Business Insider
J.P. Morgan Keeps Their Buy Rating on Merit Medical Systems (MMSI)
J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Merit Medical Systems on July 31 and set a price target of $95.00. The company's shares closed yesterday at $84.78. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Marcus covers the Healthcare sector, focusing on stocks such as Medtronic, Edwards Lifesciences, and Baxter International. According to TipRanks, Marcus has an average return of 8.8% and a 52.81% success rate on recommended stocks. In addition to J.P. Morgan, Merit Medical Systems also received a Buy from Needham's Michael Matson in a report issued on July 31. However, yesterday, TR | OpenAI – 4o reiterated a Hold rating on Merit Medical Systems (NASDAQ: MMSI). The company has a one-year high of $111.45 and a one-year low of $81.04. Currently, Merit Medical Systems has an average volume of 657.7K. Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MMSI in relation to earlier this year. Most recently, in June 2025, Raul Jr. Parra, the CFO & Treasurer of MMSI sold 15,181.00 shares for a total of $1,423,218.75.
Business Insider
a day ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO), Resmed (RMD) and Envista Holdings (NVST)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch + Lomb Corporation (BLCO – Research Report), Resmed (RMD – Research Report) and Envista Holdings (NVST – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bausch + Lomb Corporation (BLCO) J.P. Morgan analyst Robbie Marcus maintained a Hold rating on Bausch + Lomb Corporation on July 30 and set a price target of $13.00. The company's shares closed last Friday at $13.50, close to its 52-week low of $13.16. According to Marcus is a 4-star analyst with an average return of 8.8% and a 52.8% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Merit Medical Systems. Bausch + Lomb Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $14.69, implying an 8.2% upside from current levels. In a report issued on July 30, Needham also maintained a Hold rating on the stock. Resmed (RMD) J.P. Morgan analyst David Low maintained a Buy rating on Resmed yesterday and set a price target of $310.00. The company's shares closed last Friday at $279.20. According to Low is a 4-star analyst with an average return of 7.6% and a 57.0% success rate. Low covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Cochlear, and CSL. Resmed has an analyst consensus of Strong Buy, with a price target consensus of $295.40, implying a 4.8% upside from current levels. In a report released yesterday, KeyBanc also maintained a Buy rating on the stock with a $298.00 price target. Envista Holdings (NVST) J.P. Morgan analyst Rachel Vatnsdal maintained a Hold rating on Envista Holdings yesterday and set a price target of $20.00. The company's shares closed last Friday at $20.83. According to Vatnsdal is a 1-star analyst with an average return of -1.2% and a 39.3% success rate. Vatnsdal covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Twist Bioscience, and Myriad Genetics. Envista Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $22.17, which is a 9.6% upside from current levels. In a report issued on July 29, UBS also maintained a Hold rating on the stock with a $22.00 price target.
